Phibro (PAHC) Q4 2026 earnings review
Record Profits, But The Top-Line Engine Is Cooling
Phibro capped off a transformative fiscal year with $1.52B in record sales and a massive 39% jump in Adjusted EBITDA. Management executed the Zoetis MFA integration flawlessly and squeezed significant margins out of the 'Phibro Forward' initiative. However, the Q4 data reveals a sharp deceleration in top-line momentum. Revenue growth slowed to just 5% as the acquisition impact annualized, and FY27 guidance confirms this cool-down with a projected ~4% sales growth. With a looming regulatory hit in Brazil and poor free cash flow conversion, Phibro is pivoting from an acquisition-fueled growth story to a margin-defense and operational cleanup story.
🐂 Bull Case
Gross margin expanded a massive 490 basis points in Q4 to 33.9%. The 'Phibro Forward' program is structurally lowering costs, driving a 29% increase in Q4 Adjusted EBITDA on just 5% revenue growth.
The decision to close the Chicago Heights MFA facility shows management is serious about network efficiency. Relocating production will further optimize the cost base heading into a slower-growth FY27.
🐻 Bear Case
The 40% growth seen in Q1 is gone. With the Zoetis MFA acquisition fully annualized, Q4 legacy Animal Health sales grew a sluggish 2%, exposing a lack of organic top-line momentum.
Despite reporting $131.7M in Adjusted Net Income for the year, Free Cash Flow was a dismal $9.9M due to heavy working capital and inventory drags, limiting the ability to pay down $737.9M in gross debt.
⚖️ Verdict: ⚪
Neutral. The margin execution is excellent and management is prudently guiding for known risks. However, paying for top-line deceleration, Brazil regulatory overhangs, and near-zero free cash flow makes it tough to be aggressively bullish until organic volume accelerates.
Key Themes
Phibro Forward Efficiency Program
Accelerating. The internal efficiency program is the primary driver of bottom-line resilience. It fueled a 490 bps gross margin expansion in Q4 and is responsible for nearly 20% of the total guided Adjusted EBITDA for FY27. Management has proven they can extract cash from operations even when volumes slow.
Rapid Revenue Deceleration
Decelerating. The most glaring data point in this print is the top-line slowdown. Q1 grew 40%, Q2 grew 21%, Q3 grew 10%, and Q4 landed at just 5%. Animal Health, the core engine, only managed 2% growth in Q4. FY27 guidance explicitly assumes this lower trajectory (~4% growth), confirming the Zoetis acquisition tailwind has completely vanished.
Mineral Nutrition Segment Rebound
Accelerating. While Animal Health slowed, Mineral Nutrition stepped on the gas. The segment posted 20% YoY growth in Q4 to $77.0M, driven by surging demand for zinc and trace minerals. This highlights the macro tailwind of improving global livestock producer profitability and validates the company's diversified portfolio approach.
Brazil Virginiamycin Regulatory Overhang
Stable. Management's FY27 guidance takes a highly conservative stance, assuming 'minimal' sales of virginiamycin in Brazil as the country phases out growth promotion indications. While therapeutic approvals might provide an upside surprise, the immediate reality is a guaranteed near-term hit to a high-margin product that previously generated ~$26M annually.
Cash Flow Contradicts Earnings Record
Decelerating. Management touted a 'record year' with $131.7M in Adjusted Net Income. However, Free Cash Flow for the trailing twelve months was an abysmal $9.9M (down from $41.8M in FY25). This massive divergence indicates severe working capital drags and strategic inventory build-ups. If cash conversion doesn't normalize, paying down the $737.9M debt load will be mathematically impossible.
Gross Margin Expansion via Tariff Recovery
Accelerating. Beyond structural cost cuts, Q4 gross profit benefited from a net $4.3M recovery tied to tariff efforts, alongside favorable product mix. This helped mask higher baseline input costs and proves pricing/recovery levers are successfully defending profitability.
Innovation Silence: Restoris and VERRATAIN
Stable. In previous quarters, management heavily promoted the 'Restoris' companion animal dental gel and the 'VERRATAIN' sustainability platform as long-term growth vectors. The Q4 release was completely silent on these innovations. Investors need clarity on whether these products are actually scaling or just narrative filler.
Other KPIs
Accelerating. Up 490 basis points from 29.0% a year ago. Even excluding acquisition accounting adjustments, adjusted gross margin expanded 380 bps to 34.6%. This is a massive win for profitability, driven by product mix and the Phibro Forward program.
Decelerating. A major red flag. Down significantly from $41.8M in FY25, despite net income doubling. Management previously cited 'strategic inventory buildups' to get ahead of tariffs, but this working capital drain must reverse in FY27.
Accelerating. Up 18% YoY. The expiration of a favorable interest rate swap on $300M of notional debt is permanently stepping up the run-rate for debt servicing costs.
Guidance
Decelerating. The midpoint of $1.575B implies roughly 4% YoY growth. This is a hard landing from the 17% growth posted in FY26 and perfectly illustrates the reset to low single-digit organic growth now that the Zoetis MFA acquisition has annualized.
Decelerating. The midpoint implies ~3% growth, a drastic cool-down from the 39% surge in FY26. It reflects the lost margin from the assumed halt of virginiamycin sales in Brazil, offset by residual Phibro Forward savings.
Decelerating. The midpoint of $143.5M implies ~9% YoY growth, outpacing EBITDA due to expected stability in below-the-line items, though it is a stark drop from the 49% growth achieved in FY26.
Key Questions
Free Cash Flow Normalization
With only $9.9M in Free Cash Flow generated on $131.7M of Adjusted Net Income in FY26, when exactly will the 'strategic inventory buildups' reverse, and what is the normalized cash conversion target for FY27?
Organic Volume Reality
Excluding the annualized pricing benefits and the final tailwinds of the Zoetis MFA portfolio, what is the embedded organic volume growth assumption for the legacy Animal Health segment in the FY27 4% sales guide?
Brazil Contingency Plan
Your FY27 guidance assumes minimal virginiamycin sales in Brazil. If the therapeutic claim approval is ultimately denied entirely, are there permanent structural stranded costs in that region, or can the footprint be immediately rightsized?
Innovation Pipeline Updates
Previous calls heavily touted the Restoris companion animal dental gel and the VERRATAIN sustainability platform as major new growth vectors. What is their expected dollar contribution to the FY27 top-line, and why was commentary omitted from the Q4 update?